

2022 Publications:

Dibato J, Montvida O, Ling J, Koye D, Polonsky WH, Paul SK. Temporal trends in the prevalence and incidence of depression and the interplay of comorbidities in patients with young- and usual-onset type 2 diabetes from the USA and the UK. *Diabetologia* 2022; 65: 2066-2077.

Edwards S, He X, Wang W, Poon JL, Meadows E, Price D, Johnson J, Wolpert H, Polonsky W. Use of connected pen as a diagnostic tool to evaluate missed bolus dosing behavior in people with type 1 and type 2 diabetes. *Diabetes Technol Ther* 2022; 24: 61-66.

Evans M, Engberg S, Faurby M, Fernandes JDDR, Hudson P, Polonsky W. Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. *Diabetes Obes Metab* 2022; 24: 377-390.

Farooqi A, Gillies C, Sathanapally H, Abner S, Seidu S, Davies MJ, Polonsky WH, Khunti K. A systematic review and meta-analysis to compare the prevalence of depression between people with and without type 1 and type 2 diabetes. *Prim Care Diabetes* 2022; 16: 1-10.

Fisher L, Polonsky WH, Perez-Nieves M, Desai U, Strycker L, Hessler D. A new perspective on diabetes distress using the type 2 diabetes distress assessment system (T2-DDAS): Prevalence and change over time. *J Diabetes Complications* 2022. doi: 10.1016/j.jdiacomp.2022.108256.

Fisher L, Fortmann A, Knaebel J, Stuhr A. Can a basic management app paired with a glucose meter help reduce glucose levels among adults with type 2 diabetes? The REALL study. *J Diabetes Sci Technol* 2022. doi: 10.1177/19322968221096163.

Hessler D, Fisher L, Dickinson M, Dickinson P, Parra J, Potter MB. The impact of enhancing self-management support for diabetes in Community Health Centers through patient engagement and relationship building: a primary care pragmatic cluster-randomized trial. *Transl Behav Med* 2022; 12: 909-918.

Masharani U, Strycker LA, Fisher L. The ubiquity of diabetes distress among adults with type 1 diabetes in an urban, academic practice: A template for intervention. *Diabet Med* 2022. doi: 10.1111/dme.14832.

Polonsky WH, Fortmann AL, Soriano EC, Guzman SJ, Funnell MM. The AH-HA! project: Transforming group diabetes self-management education through the addition of flash glucose monitoring. *Diabetes Technol Ther* 2022. doi: 10.1089/dia.2022.0419. Online ahead of print.

Polonsky WH, Giorgino F, Rosenstock J, Whitmire K, Lew E, Coudert M, Alvarez A, Nicholls C, McCrimmon RJ. Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial. *Diabetes Obes Metab* 2022; 24: 2364-2372.

Polonsky WH, Hood KK, Levy CJ, MacLeish SA, Hirsch IB, Brown SA, Bode BW, Carlson AL, Shah VN, Weinstock RS, Bhargava A, Jones TC, Aleppo G, Mehta SN, Laffel LM, Forlenza GP, Sherr JL, Huyett LM, Vienneau TE, Ly TT; Omnipod 5 Research Group. How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System. *Diabetes Res Clin Pract* 2022. doi: 10.1016/j.diabres.2022.109998.

Polonsky WH, Soriano EC, Fortmann AL. The role of retrospective data review in the personal use of real-time continuous glucose monitoring: Perceived impact on quality of life and health outcomes. *Diabetes Technol Ther* 2022; 24: 492-501.

Polonsky WH, Arora R, Faurby M, Fernandes J, Liebl A. Higher rates of persistence and adherence in patients with type 2 diabetes initiating once-weekly vs daily injectable glucagon-like peptide-1 receptor agonists in US clinical practice (STAY study). *Diabetes Ther* 2022; 13: 175-187.

Polonsky WH, Fisher L, Hessler D, Desai U, King SB, Perez-Nieves M. Toward a more comprehensive understanding of the emotional side of type 2 diabetes: A re-envisioning of the assessment of diabetes distress. *J Diabetes Complications* 2022. doi: 10.1016/j.jdiacomp.2021.108103.

Soriano EC, Polonsky WH. The influence of real-time continuous glucose monitoring on psychosocial outcomes in insulin-using type 2 diabetes. *J Diabetes Sci Technol* 2022. doi: 10.1177/19322968221094831.